Hashimoto’s encephalopathy is a rare, autoimmune-related brain condition marked by cognitive decline, seizures, and psychiatric symptoms in people who have high levels of antithyroid antibodies in their blood. Despite its name, the condition does not appear to be caused by thyroid disease itself, and most patients have normal or only mildly off thyroid function when symptoms strike. What makes it especially important to recognize is that it responds remarkably well to steroid treatment, meaning a correct diagnosis can reverse symptoms that otherwise look like devastating, untreatable neurological disease.
How It Got Its Name and Why That Name Is Controversial
The condition is named after Hashimoto’s thyroiditis, the common autoimmune thyroid disorder, because the two share the same circulating antibodies against thyroid tissue. But the name has frustrated neurologists for decades. A key criticism is that calling it “Hashimoto’s encephalopathy” implies the thyroid disease is causing the brain symptoms, and there is no solid evidence that this is true. Many researchers prefer the term “steroid-responsive encephalopathy associated with autoimmune thyroiditis,” or SREAT, because it describes what is actually observed without assuming a causal link to the thyroid gland itself.1JAMA Neurology. Steroid-Responsive Encephalopathy Associated With Autoimmune Thyroiditis Some researchers have even questioned whether the condition is a distinct entity at all, or simply an unexplained encephalopathy that happens to occur in people who, like a sizable chunk of the general population, test positive for antithyroid antibodies.2JAMA Neurology. Hashimoto Encephalopathy: Syndrome or Myth?
This debate is not just academic. Because antithyroid antibodies are found at elevated levels in otherwise healthy people, simply having those antibodies alongside brain symptoms does not prove one is causing the other. The antibodies may be a marker of a broader autoimmune process rather than the agents doing the damage. Still, the name “Hashimoto’s encephalopathy” has stuck in clinical practice, and you will see it used interchangeably with SREAT in medical literature.
Who Gets It
Hashimoto’s encephalopathy is rare. Exact prevalence is hard to pin down because it is widely believed to be underdiagnosed, but available data suggest it overwhelmingly affects women, who account for roughly 70 to 88 percent of reported cases. The female-to-male ratio sits around 4 to 1, and the average age of onset is about 40.3PubMed Central. Hashimoto encephalopathy: a case report and a short revision of current literature That said, the condition has been documented across a wide age range, from toddlers to the elderly. In children, a review of 100 published pediatric cases found a mean age of about 11, and the female predominance held there too, with 78 out of 100 patients being girls.4PubMed. Clinical characteristics of paediatric Hashimoto’s encephalopathy
The Symptoms Are Alarmingly Varied
One reason Hashimoto’s encephalopathy is so difficult to catch is that it does not produce a single, recognizable pattern. The symptoms span a wide range of neurological and psychiatric territory. Cognitive changes and seizures are the most commonly reported features at onset.5PubMed. Hashimoto Encephalopathy Presenting With Stroke-Like Episodes in an Adolescent Female: A Case Report and Literature Review Beyond those, reported symptoms include disturbances of consciousness, memory loss, involuntary muscle jerks (myoclonus), hallucinations, stroke-like episodes, tremor, other involuntary movements, language problems, and difficulty walking.6PubMed. Hashimoto’s encephalopathy: report of three cases
The condition tends to fall into two broad clinical patterns, though plenty of overlap exists. One pattern involves sudden, stroke-like episodes or seizures with periods of relative stability in between. The other is a more gradual, progressive decline in thinking and awareness that can look like dementia. Some patients present with a mix of both.
When Psychiatric Symptoms Come First
A particularly tricky scenario occurs when the earliest symptoms are psychiatric rather than neurological. A systematic review of cases where psychiatric presentations heralded the diagnosis found that the most common initial psychiatric diagnosis was acute psychosis, accounting for about a quarter of cases, followed closely by depressive disorders at roughly the same rate. Dementia and schizophrenia-like presentations were less common but documented.7PubMed Central. Psychiatric Presentations Heralding Hashimoto’s Encephalopathy: A Systematic Review and Analysis of Cases Reported in Literature Case reports describe patients admitted to psychiatric wards with sudden-onset delusions, visual and tactile hallucinations, and disorganized behavior before anyone thought to check thyroid antibodies.8PubMed Central. Psychotic Symptoms of Hashimoto’s Encephalopathy: A Diagnostic Challenge9PubMed. Debut with psychotic symptoms of Hashimoto encephalopathy: A case report
This matters because a patient who arrives with acute psychosis will typically receive antipsychotic medications, which may partially mask the symptoms without treating the underlying cause. Meanwhile, the autoimmune process continues. The psychiatric literature has increasingly urged clinicians to include antithyroid antibody testing in the workup of unexplained new-onset psychosis, especially in women and when other features like seizures or confusion accompany the psychiatric symptoms.
How Children Present Differently
In children and adolescents, the symptom profile shifts somewhat. Seizures are even more dominant, appearing in 79 out of 100 pediatric cases reviewed in one large analysis, with a quarter of those children experiencing full-blown status epilepticus. Behavioral problems, hallucinations, headaches, and declining school performance were also common.4PubMed. Clinical characteristics of paediatric Hashimoto’s encephalopathy Another case series in younger patients found breath-holding spells, behavioral outbursts, psychosis, and difficulty with coordination among the presenting features, and importantly, most of those children had normal thyroid function at the time.10Pediatric Neurology. Hashimoto’s encephalopathy in children and adolescents The diagnosis is even less commonly suspected in younger patients, so pediatricians and child neurologists have to maintain a high index of suspicion.
What Causes It, and What the Thyroid Has to Do With It
The honest answer is that the exact cause remains unclear, which is why the condition still generates more questions than answers among researchers. What is established is that the condition involves autoimmune activity, and that it occurs in people with elevated antithyroid antibodies, specifically antibodies against thyroid peroxidase (anti-TPO) and against thyroglobulin (anti-TG). Every confirmed case, by definition, shows elevated levels of one or both of these antibodies.
Here is the puzzle: thyroid function itself is typically normal. In over 70 percent of reported cases, patients are either euthyroid (meaning their thyroid hormones are in the normal range) or only subclinically hypothyroid, and the severity of any thyroid imbalance does not track with how sick the patient is neurologically.11PubMed Central. Hashimoto Encephalopathy—Still More Questions than Answers This disconnect is a major reason researchers doubt that thyroid dysfunction itself is driving the brain symptoms. You can have raging Hashimoto’s thyroiditis with wildly high antibody levels and never develop encephalopathy, or you can develop the encephalopathy while your thyroid numbers look perfectly fine.
Are the Antibodies Doing the Damage?
One leading hypothesis is that antithyroid antibodies are not themselves pathogenic but instead serve as markers of a broader autoimmune tendency, with the real damage being done by a separate immune-mediated process directed at the brain. The antithyroid antibodies can be detected at elevated levels in the healthy general population, which makes them an imperfect diagnostic tool and casts doubt on them being the direct cause.12Springer. Hashimoto’s encephalopathy : epidemiology, pathogenesis and management
A more promising candidate involves autoantibodies against a protein called alpha-enolase, specifically its amino-terminal region. One study found these antibodies in over 80 percent of patients with Hashimoto’s encephalopathy but in only about 12 percent of patients with Hashimoto’s thyroiditis alone, and in none of the healthy or neurologically ill controls tested.13PubMed. Autoantibodies against the amino terminal of alpha-enolase are a useful diagnostic marker of Hashimoto’s encephalopathy Alpha-enolase is expressed in brain tissue, and these antibodies may be involved in the autoimmune process that produces the encephalopathy, potentially including vasculitis (inflammation of blood vessels in the brain).14PubMed. Serial brain MRI changes related to autoimmune pathophysiology in Hashimoto encephalopathy with anti-NAE antibodies: A case-series study This line of research is still evolving, but anti-alpha-enolase antibodies are considered the most specific biomarker identified so far for the condition.
Some cases also show direct evidence of blood vessel inflammation in the brain. One reported case in a 52-year-old woman with recurrent stroke-like episodes showed abnormalities on cerebral angiography consistent with central nervous system vasculitis, and both the symptoms and the angiographic findings resolved completely after corticosteroid treatment.15PubMed Central. Hashimoto encephalopathy with angiographic CNS vasculitis Not all patients show vasculitis, which suggests the condition may involve more than one mechanism or may represent a spectrum of related autoimmune brain inflammation rather than a single disease.
How It Gets Diagnosed
There is no single definitive test for Hashimoto’s encephalopathy. The diagnosis is made by putting together a clinical picture: unexplained encephalopathy plus high antithyroid antibodies, after systematically ruling out other causes. A few investigations help build the case.
Brain MRI is normal in roughly half of patients. When it does show abnormalities, the most common findings are generalized brain shrinkage, patchy bright signals in the white matter on certain scan sequences, and sometimes enhancement of the membrane lining the brain.16PubMed Central. Hashimoto’s encephalopathy The fact that a clean MRI does not rule out the condition is important to understand; a clinician who dismisses the diagnosis because the scan looks normal may miss it entirely.
A spinal tap typically reveals elevated protein in the cerebrospinal fluid without a significant increase in white blood cells. Antithyroid antibodies have been found in the spinal fluid of affected patients as well, suggesting that the immune process involves the central nervous system directly rather than just spilling over from the bloodstream.17Journal of Experimental Neurology. Hashimoto’s Encephalopathy: A Review EEG recordings generally show slowing of brain activity, sometimes with frontal-predominant rhythmic patterns; two patients in one early series also had triphasic waves, a pattern that can mimic metabolic encephalopathy or prion disease.18PubMed. Electroencephalographic findings in Hashimoto’s encephalopathy19PubMed. Manifestation of Hashimoto’s encephalopathy years before onset of thyroid disease
Conditions It Mimics
Because Hashimoto’s encephalopathy has no pathognomonic test and its symptoms overlap with so many other brain diseases, diagnosis depends heavily on excluding alternatives. Two mimics deserve special attention.
The first is Creutzfeldt-Jakob disease (CJD), the rapidly fatal prion disease. Both conditions can produce fast cognitive decline, myoclonus, and EEG abnormalities. The resemblance has fooled clinicians on multiple occasions. A key distinguishing feature is that CJD patients typically test positive for the 14-3-3 protein in their spinal fluid and show periodic sharp-wave complexes on EEG, while Hashimoto’s encephalopathy patients do not show either of those findings.20PubMed Central. Hashimoto’s encephalitis as a differential diagnosis of Creutzfeldt-Jakob disease The distinction matters enormously: CJD is untreatable and fatal within months, whereas Hashimoto’s encephalopathy often reverses quickly with steroids. Physicians have been urged to consider antithyroid antibody testing in patients with rapid cognitive decline and no clear cause, precisely to avoid missing this treatable mimic.21PubMed. Hashimoto’s encephalopathy mimicking Creutzfeldt-Jakob disease
The second category of conditions to rule out is other forms of autoimmune encephalitis, particularly those caused by antibodies against neuronal surface proteins. Conditions like anti-NMDA receptor encephalitis, anti-LGI1 encephalitis, and anti-IgLON5 disease can produce overlapping symptoms and also respond to immune treatment. Proper diagnosis of Hashimoto’s encephalopathy requires testing for these neuronal surface antibodies and for paraneoplastic antibodies to make sure a different and more specific autoimmune encephalitis is not being missed.22PubMed Central. Hashimoto’s Encephalopathy: Case Series and Literature Review
Treatment and How Well It Works
Corticosteroids are the first-line treatment, and the response is often dramatic. In the largest published analysis, which pooled 251 cases from the literature, steroids were the initial treatment in the vast majority. At a median follow-up of 12 months, about 91 percent of patients showed complete or partial neurological improvement.23PubMed. Steroid-responsive encephalopathy associated with autoimmune thyroiditis (SREAT): Characteristics, treatment and outcome in 251 cases from the literature High-dose intravenous steroids are often used during acute episodes, followed by a gradual taper to oral steroids for maintenance.
The fact that the condition responds so well to steroids is both its defining clinical feature and a therapeutic clue. It also feeds back into the naming debate: the response to steroids is so central to the diagnosis that some researchers argue the condition should be defined by it.
Not everyone responds to steroids alone, though. For patients who are steroid-refractory or who suffer intolerable side effects from long-term steroid use, other immune-modifying treatments have been used. These include azathioprine, mycophenolate, cyclophosphamide, methotrexate, intravenous immunoglobulin, and rituximab.24PubMed Central. The use of intravenous immunoglobulin in the treatment of Hashimoto’s encephalopathy: case based review Some cases require long-term treatment with a combination of steroids and other immunomodulatory agents to prevent relapse.25PubMed. Long-term treatment of Hashimoto’s encephalopathy Rituximab, a drug that targets B cells of the immune system, has shown promise in steroid-refractory adolescents, though it carries the risk of lowering immunoglobulin levels and requires careful monitoring.26PubMed. Risks and Benefits of Rituximab in the Treatment of Hashimoto Encephalopathy in Children: Two Case Reports and a Mini Review
Relapse and Long-Term Outlook
While the initial treatment response is usually encouraging, relapse is a known risk. Some patients do well after a single course of steroids and never have another episode. Others relapse as steroids are tapered, and a subset develop a chronic relapsing-remitting course that requires ongoing immune suppression. In the pediatric review mentioned earlier, most children (70 out of 100) recovered fully, but 16 had lasting effects, most commonly ongoing epilepsy.4PubMed. Clinical characteristics of paediatric Hashimoto’s encephalopathy
Even when overt symptoms resolve, subtler cognitive effects can linger. Neuropsychological testing in at least one detailed case revealed a pattern of thinking difficulties more typical of subcortical brain disease, including slowed processing, executive dysfunction, and memory retrieval problems, along with neuropsychiatric symptoms that significantly affected daily functioning and quality of life.27PubMed. Hashimoto encephalopathy: a literature review and case report with comprehensive neuropsychological evaluation The extent to which these residual deficits are common is not well studied, largely because the condition itself is so rare that assembling large cohorts for follow-up research is difficult.
Why It Gets Missed
Several features of Hashimoto’s encephalopathy conspire to make it easy to overlook. The symptoms are nonspecific and overlap with a long list of more common conditions, from epilepsy to schizophrenia to dementia. The thyroid connection is not intuitive; most clinicians do not think to order antithyroid antibodies when evaluating confusion or seizures. The MRI is often unrevealing. And the rarity of the condition means many doctors have never seen a case.
Perhaps the most insidious factor is that the condition can appear years before any clinical thyroid disease develops.19PubMed. Manifestation of Hashimoto’s encephalopathy years before onset of thyroid disease A patient who has never been diagnosed with a thyroid problem and has normal thyroid hormone levels will not trigger the mental link to autoimmune thyroid disease in most clinicians’ minds. The practical takeaway for patients and their families is worth remembering: if someone develops unexplained cognitive decline, seizures, or psychiatric symptoms, particularly if they are female and there is a personal or family history of autoimmune disease, asking about antithyroid antibody testing is reasonable.
The Ongoing Scientific Identity Crisis
Hashimoto’s encephalopathy remains a diagnosis without a universally accepted mechanism, a specific biomarker in routine clinical use, or even an agreed-upon name. The anti-alpha-enolase antibodies show the most specificity so far, but testing for them is not widely available outside research settings. The antithyroid antibodies that define the condition are common in the general population and do not appear to be the actual cause of brain inflammation. And the dramatic steroid response, while clinically useful, is not unique to this condition.
What keeps the diagnosis alive and clinically useful is the practical reality that a recognizable pattern of symptoms exists, that it occurs with high antithyroid antibodies, that ruling out other causes is important, and that steroid treatment works. For patients and families navigating the diagnosis, the uncertainties about mechanism and naming matter less than the fact that the condition is treatable. The risk lies in the other direction: in the condition going unrecognized because it does not fit neatly into any single specialty’s territory, falling between neurology, endocrinology, and psychiatry in a way that allows patients to bounce between specialists without anyone ordering the right blood test.